The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site in Australia.

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...

US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.

Fermented bamboo shoots, a staple in India’s northeastern cuisine, are superfoods celebrated for their health benefits, which ...

Edison is looking to protect and promote public health by controlling the growth of bamboo in town An ordinance slated to be introduced on Wednesday would ban the planting of bamboo on property ...

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced today a poster presentation at SECO 2025 being held from February 26 ? March 2 in Atlanta, Georgia. Mile Brujic, OD, FAAO of Premier ...

Tori Lyon, CEO of Jericho Project, the nationally-acclaimed nonprofit ending homelessness in New York, rang the closing bell of the New York Stock Exchange on February 21, 2025, in celebration of the ...

Bambusa’s lead candidate BBT001 is being investigated for dermatologic indications. Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to ...

Bambusa Therapeutics raised around $90 million in a series A round Friday to drive the development of bispecific antibodies for immunological and inflammatory disorders. The Boston-based company was ...

Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting ...

GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the field of dermatology, Bambusa Therapeutics has announced the dosing of its first healthy volunteers as part of a Phase I ...